The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study
Open accessAbstract
Voretigene neparvovec (VN) is the first available gene therapy for patients with biallelic RPE65-mediated inherited retinal dystrophy who have sufficient viable retinal cells. PERCEIVE is an ongoing, post-authorization, prospective, multicenter, registry-based observational study and is the largest study assessing the real-world, long-term safety and effectiveness of VN. Here, we present the outcomes of 103 patients treated with VN according to local prescribing information. The mean (SD) age was 19.5 (10.85) years, 52 (50.5%) were female, and the mean (SD) duration of the follow up was 0.8 (0.64) years (maximum: 2.3 years). Thirty-five patients (34%) experienced ocular treatment-emergent adverse events (TEAEs), most frequently related to chorioretinal atrophy (n = 13 [12.6%]). Eighteen patients (17.5%; 24 eyes [13.1%]) experienced ocular TEAEs of special interest, including intraocular inflammation and/or infection related to the procedure (n = 7). The mean (SD) changes from baseline in full-field light-sensitivity threshold testing (white light) at month 1, month 6, year 1, and year 2 were −16.59 (13.48) dB (51 eyes), −18.24 (14.62) dB (42 eyes), −15.84 (14.10) dB (10 eyes), and −13.67 (22.62) dB (13 eyes), respectively. The change in visual acuity from baseline was not clinically significant. Overall, the outcomes of the PERCEIVE study are consistent with the findings of VN pivotal clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This prevalence is also seen in post-approval studies of voretigene neparvovec (Kessel et al., 2022; Fischer et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Fischer et al., 2024
The cited source says what the claim attributes to it.
In the citing paper
“Most patients have undergone second eye treatment 7 days after the first eye in real-world use (Fischer et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Fischer et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“In these trials, VN administration to patients with biallelic RPE65 -associated IRD led to improvements in functional vision (multi-luminance mobility test) and visual function (full-field light-sensitivity threshold (FST) and VF) [13–15].”
BackgroundSelf-citationLange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K., & Bach, M. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0926-0 · Cited by 626 · cited 1×
“Off-chart vision measurements were assigned values using the scale adapted from Lange 2009 [21].”
MethodMaguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409
Self-citationDurability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease
Maguire, A. M., Russell, S., Chung, D. C., Yu, Z.-F., Tillman, A., Drack, A. V., Simonelli, F., Leroy, B. P., Reape, K. Z., High, K. A., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.03.031 · Cited by 194 · cited 3×
“In these trials, VN administration to patients with biallelic RPE65 -associated IRD led to improvements in functional vision (multi-luminance mobility test) and visual function (full-field light-sensitivity threshold (FST) and VF) [13–15].”
BackgroundMethodResultSelf-citationRetinal Inflammation, Cell Death and Inherited Retinal Dystrophies
Olivares‐González, L., Velasco, S., Campillo, I., & Rodrigo, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042096 · Cited by 162
Gange, W. S., Sisk, R. A., Besirli, C. G., Lee, T. C., Havunjian, M., Schwartz, H., Borchert, M., Sengillo, J. D., Mendoza‐Santiesteban, C. E., Berrocal, A. M., et al. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.03.016 · Cited by 157
Chiu, W., Lin, T.-Y., Chang, Y.-C., Lai, H. I. A. M., Lin, S.-C., Ma, C., Yarmishyn, A. A., Lin, S.-C., Chang, K.-J., Chou, Y.-B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094534 · Cited by 115
Retinal pigment epithelium 65 kDa protein (RPE65): An update
Kiser, P. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101013 · Cited by 102 · cited 2×
“The RPE65 gene is selectively expressed in retinal pigment epithelium (RPE) cells and encodes the 65-kDa retinoid isomerohydrolase, which converts all-trans -retinyl ester to 11-cis -retinal, an essential step in the regeneration of visual pigment [4,5].”
BackgroundVoretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence
Gao, J., Hussain, R. M., & Weng, C. Y. (2020) · Clinical ophthalmology · doi:10.2147/opth.s231804 · Cited by 86 · cited 1×
“Furthermore, the results show an acceptable safety profile, which is consistent with vitrectomy and the subretinal administration procedure [11,13,14].”
ResultDevelopment of retinal atrophy after subretinal gene therapy with voretigene neparvovec
Reichel, F. F., Seitz, I. P., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-321023 · Cited by 84
Self-citation
Research works printed but not linked: 1
- Isabelle Audo, J.A.S., Barale, P.O., Said, S.M., Devisme, C., Pagot, C., and Chapn, P. (2022, January 21). LIGHT—Observational study on the use of voretigene neparvovec in patients with inherited retinal dystrophy at CHNO des Quinze-Vingts: A 1-year follow-up of a 12-case series. Proceedings of the EURETINA—European Society of Retina Specialists, Hamburg, Germany.
Cited by
Gene therapies for neurogenetic disorders
Devinsky, O., Coller, J., Ahrens‐Nicklas, R. C., Liu, X. S., Ahituv, N., Davidson, B. L., Bishop, K. M., Weiss, Y., & Mingorance, A. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.01.015 · Cited by 33
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Self-citationMichaelides, M., Laich, Y., Wong, S. C., Oluonye, N., Zaman, S., Kumaran, N., Kalitzeos, A. A., Petrushkin, H., Georgiou, M., Tailor, V., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02812-5 · Cited by 24
“31,32 Subretinal administration of voretigene neparvovec has been reported in children as young as 2 years of age, with measurable improvements in visual acuity in children aged 3–6 years.”
Gene therapy strategies in ophthalmology—an overview of current developments and future prospects
Krajewska, J. B., & Waszczykowska, A. (2025) · Journal of Applied Genetics · doi:10.1007/s13353-025-00973-5 · Cited by 19
“Although the patient population is still very limited, real-world studies provide additional information especially concerning rare adverse events (Sengillo et al. 2022; Deng et al. 2022; Testa et al. 2022; Kiraly et al. 2023; Fischer et al. 2024; Melillo et al. 2024).”
Jia, R., Chen, S., Wang, L., Zhang, J., Qu, B., Qiao, J., Meng, X., Yu, S., Liu, X., Xu, B., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101377 · Cited by 17
“AAV8 is about 10-fold more efficient than AAV2 at transducing RPE and photoreceptor cells with subretinal injection in NHP (Vandenberghe et al., 2011).”
Gene Therapy for Achromatopsia
Baxter, M. F., & Borchert, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179739 · Cited by 14
The versatile roles of retinal pigment epithelium in the pathophysiology of retinitis pigmentosa
Ghanawi, H., & Koch, S. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101390 · Cited by 14
Insights into eye genetics and recent advances in ocular gene therapy
Szabó, V., Varsányi, B., Barboni, M. T. S., Takács, Á. I., Knézy, K., Molnár, M. J., Nagy, Z. Z., György, B., & Rivolta, C. (2025) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2025.102008 · Cited by 16
Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants
Scruggs, B. A., Berger, A., Knudsen, T., Kopp, F. N., Hill, M., Trncic, E., Anderson, K., Iezzi, R., & Marmorstein, A. D. (2025) · Science Advances · doi:10.1126/sciadv.adv7922 · Cited by 13
“Although the patient experience has been generally positive after Luxturna ( 2 – 5 ), there are several major limitations and challenges of administering any retinal gene therapy by subretinal injection.”
InfluentialShining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Machado, T., Soares, M., Raimundo, M., Lemos, L., Pina, P., Carvalho, A. L., Alfaiate, M., Figueira, J., & Marques, J. P. (2026) · Eye · doi:10.1038/s41433-026-04467-4 · Cited by 10
Clinical and pharmacovigilance safety evaluation of LUXTURNA ® (voretigene neparvovec-rzyl)
Simoens, D., Shravah, V., Jones, W. K., & Kaja, S. (2025) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2025.2573463 · Cited by 13
“Glybera® (alipogene tiparvovec), approved only in europe for lipoprotein lipase deficiency, was withdrawn due to low demand and a price of €1.1 million (~$1.3 million) per treatment [67].”
InfluentialThompson, D. A., Jayasundera, T., Alekseev, O., Ali, R. R., Amato, A., Arshavsky, V. Y., Audo, I. S., Auricchio, A., Bainbridge, J. W., Banin, E., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.8.37 · Cited by 8
Self-citationSelection of UTRs in mRNA-Based Gene Therapy and Vaccines
Volkhin, I. A., Paremskaia, A. I., Dashian, M. A., Smeshnova, D. S., Pavlov, R. E., Mityaeva, O. N., Volchkov, P. Y., & Deviatkin, A. A. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297924604659 · Cited by 7
AlEissa, M. M., Alhawsawi, A. A., Alonazi, R. H., Magharbil, E., Aljahdali, A., ALBalawi, H. B., Alali, N. M., Hameed, S., Abu‐Amero, K. K., & Magliyah, M. (2025) · Genes · doi:10.3390/genes16070847 · Cited by 8
Fujinami, K., Akiyama, K., Tsunoda, K., Ito, S., Seko, N., & Yamamoto, S. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100876 · Cited by 7
“…site or in other retinal regions has been reported in approximately 12% to 28% of cases over a period of months to years following treatment, 42,43,45 greater improvements in FST were reported among patients who developed chorioretinal atrophy, 43 although the underlying etiology remains to…”
InfluentialButt, F. R., Dhivagaran, T., Li, B., Ashamalla, M., Tao, B. K.-L., Balas, M., Pereira, A., Yan, P., & Arjmand, P. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120619 · Cited by 8
“Further validation has come from interim analyses of the PERCEIVE study, the largest real-world registry of VN-treated patients to date [24].”
Influential“Blindness” is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 cases
Parameswarappa, D. C., Stephenson, K. A. J., Seamone, M. E., Qian, C. X., Muni, R. H., Kertes, P. J., Vincent, A., & Héon, E. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2024.12.013 · Cited by 6
Fukushima, M., Tao, Y., Shimokawa, S., Zhao, H., Shimokawa, S., Funatsu, J., Hisai, T., Okita, A., Fujiwara, K., Hisatomi, T., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100582 · Cited by 5
“2, 14 It has been shown that retinal sensitivity values measured by both MP (MAIA, microperimetry-1, and MP-3) and SAP (Octopus and HFA) are well correlated with retinal anatomical parameters.”
Berger, A., Johnson, C. D., Marmorstein, A. D., & Scruggs, B. A. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14593 · Cited by 6
Applications of Modern Cell Therapies: The Latest Data in Ophthalmology
Iliadis, I., Печникова, Н. А., Poimenidou, M., Almaliotis, D. D., Tsinopoulos, I., Yaremenko, T. V., & Yaremenko, A. V. (2025) · Life · doi:10.3390/life15101610 · Cited by 4
Egorova, T. V., Piskunov, A. A., & Poteryaev, D. A. (2024) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2024-24-2-123-139 · Cited by 5
Foveal detachment in voretigene neparvovec administration: essential step or avoidable risk?
Király, P., Ivanova, T., & Jalil, A. (2025) · Eye · doi:10.1038/s41433-025-03672-x · Cited by 4
“The PERCEIVE study confirmed these real-world improvements in hundreds of patients [4], and long-term follow-up, up to 7.5 years, further validated the durability of these gains [5].”
InfluentialLorenz, B. (2025) · Medizinische Genetik · doi:10.1515/medgen-2024-2067 · Cited by 10
Novel photoreceptor-specific promoters for gene therapy in mid- to late-stage retinal degeneration
Sudharsan, R., Murgiano, L., Ahuja, A., Sato, Y., Kwok, J., Dolgova, N., Savina, S., Sedorovitz, M., Dufour, V., Aguirre, G. K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.020 · Cited by 4
Real-world outcomes of Voretigene Neparvovec: a single-centre consecutive case series
Jalil, A., Ferrara, M., Lippera, M., Parry, N. R. A., Black, G. C. M., Banderas, S., Ashworth, J. L., Biswas, S., Hall, G., Gray, J., et al. (2025) · Eye · doi:10.1038/s41433-025-03637-0 · Cited by 5
Matczyńska, E., Szymańczak, R., Stradomska, K., Łyszkiewicz, P., Jędrzejowska, M., Kamińska, K., Beć-Gajowniczek, M., Suchecka, E., Zagulski, M., Wiącek, M. P., et al. (2024) · Genes · doi:10.3390/genes15081011 · Cited by 3
Subretinal Injection Volume Correlates to Persistent Outer Retinal Thinning in the Pig Eye
Seitz, I. P., Nyshchuk, R., Ellederová, Z., Ardan, T., Juhásová, J., Nemesh, Y., Juhás, Š., Drutovič, S., Süßkind, D., Schnichels, S., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.14.27 · Cited by 3
“44 So far, no clear picture has emerged on whether treatment outcomes in VN correlate to the used SRV.”
Self-citationCas9-targeted-based long-read sequencing for genetic screening of RPE65 locus
Rodilla, C., Núñez‐Moreno, G., Benítez, Y., Romero, R., Fernández‐Caballero, L., Mínguez, P., Cortón, M., & Ayuso, C. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1439153 · Cited by 2
Most, J. A., Le, A. D., Tran, M. D., Walker, E. H., Swamy, A., Bartsch, D., Freeman, W. R., Nguyen, T. Q., An, C., & Borooah, S. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100889 · Cited by 2
“7,8 To facilitate these trials and provide accurate prognostic information to patients, it is crucial for researchers and clinicians to have the ability to assess and monitor disease progression.”
Fischer, M. D., Audo, I. S., Gaucher, D., Holz, F. G., Kessel, L., Russell, S., Katarina, Š., Rousso, D. L., Maier, R., Clemens, A., et al. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101090 · Cited by 2
“28 Other researchers documenting cases of CRA after VN did not observe any signs of inflammation in their patients.”
Self-citationRare pediatric retinal diseases: A review
Vinekar, A. S., Wu, W.-C., Lorenz, B., Bavaskar, S., Berrocal, A. M., López-Cañizares, A., Fung, N. S. K., Lam, W., Llop, S. M., Mangalesh, S., et al. (2025) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1542_24 · Cited by 2
“[48] Our monocentric study on 30 eyes and others confirm better outcomes in less advanced disease, particularly in younger patients.”
Leung, A., Perdigão, P. R. L., Sacristán-Reviriego, A., Sladen, P. E., Aguzzi, E. A., Rezek, F. O., Ziaka, K., Guarascio, R., Hau, K.-L., Cheetham, M. E., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102777 · Cited by 1
Sassen, S. H., Saßmannshausen, M., Sassen, J., Preising, M. N., Scholz, J. P., Holz, F. G., Lorenz, B., & Herrmann, P. (2025) · Ophthalmologica · doi:10.1159/000549548 · Cited by 2
“Other studies report incidences varying from 12.6% (13/103, PERCEIVE study [12]) over 27–83% [8, 14].”
InfluentialSelf-citationGene therapy outcomes in young patients with RPE65-retinal degeneration
STEPHENSON, K., Alsalamah, A. K., Tumber, A. K., Mercer, G., Ballios, B. G., Muni, R. H., Tavares, E. S., Kertes, P. J., Vincent, A., & Héon, E. (2026) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2026.01.016 · Cited by 1
Zhao, P., Gao, Y., Qiu, H., & Jin, L. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05092-4 · Cited by 1
“Its efficacy has been confirmed in multiple clinical trials, demonstrating significant improvements in visual function and offering a groundbreaking treatment strategy targeting the underlying disease mechanism (Fischer et al. 2024).”
Langer, P. M., Clare, A. J., Peng, X., Costello, K. L., Cendanawati, S., Wilson, L. L., Ward, A., Bell, O. H., Chu, C. J., Chan, Y., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.018 · Cited by 1
“59,60 Additionally, our recent work showed that an enhanced dysregulated microglia phenotype at 28 dpi was linked to tissue degeneration in aged female mice, highlighting the risk that this change in signature can pose.”
Sourd, C., Quinn, J., John, M. C., de la Cámara, C. M.-F., Wickramasinghe, L. C., Attar, M., Shamsnajafabadi, H., Salman, A., Cowley, S. A., Dendrou, C. A., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201726 · Cited by 2
“7,34,35 The mechanism of CRA remains unclear.”
Hasan, N., Attaway, C. A., Paolo, M. D., McCall, M. A., & Gregg, R. G. (2026) · Gene Therapy · doi:10.1038/s41434-026-00633-1 · Cited by 1
“…diseases) is a proven approach, with FDA approval in 2017 of Luxturna, an rAAV approach to treat mature and juvenile patients with a form of Leber ’ s congenital amaurosis (LCA2), caused by biallelic null mutations in RPE65 , and better outcomes are reported when younger patients are treated [35].”
Király, P., Ivanova, T., & Jalil, A. (2026) · Eye · doi:10.1038/s41433-026-04830-5 · Cited by 1
Ciccioli, M., & Antacle, A. (2024) · Oftalmología clínica y experimental. · doi:10.70313/2718.7446.v17.n01.284 · Cited by 2
Precision ophthalmology: a call for Africa not to be left in the dark
Roberts, L. J. (2024) · Gene Therapy · doi:10.1038/s41434-024-00448-y · Cited by 1
“…before it reached the market in 2017; (3) the treatment currently costs $850,000 ($425,000 per eye); and (4) subsequent to authorisation for market use, chorioretinal atrophy was identi fi ed as an adverse event through the long-term monitoring of patients who have received the gene therapy [6, 7].”
BackgroundFry, L. E., Britten‐Jones, A. C., Gocuk, S. A., Ayton, L. N., & Mack, H. G. (2025) · Seminars in Ophthalmology · doi:10.1080/08820538.2025.2524057
“27,28 However, invitations for testing were only offered to adults over 18 years of age due to complexities of consent obtained over the internet for individuals under 18 years, thereby excluding the most typical cohort of patients with early onset severe IRD, which might be due to RPE65 pathogenic…”
Abdul, R., Liu, X., Choi, K., Huang, M., Mack, H. G., & Savige, J. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.11.73
One down but many more to go: the state of gene therapy for inherited retinal disease
Tan, T., Sun, C., Poh, S. S. J., Lim, J., Teo, J. X. J., Dey, S., Chua, Z., Guo, J., Wang, Z., Tay, H. G., et al. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2571360
Leber congenital amaurosis: Ocular Genetic Studies
Polat, E., & Güngel, H. (2025) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0529
RPE65-associated Retinal Diseases and Ocular Genetic Studies
Erol, M. A., & Kaplan, F. B. (2025) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0522
Grönholm, E., & Nättinen, J. E. (2024) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)
John, M. C., de la Cámara, C. M.-F., Salman, A., Staurenghi, F., Shamsnajafabadi, H., McClements, M. E., Cehajic‐Kapetanovic, J., Bray, A., Fischer, M. D., Dick, A. D., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201652
“…Inc., Philadelphia, USA) is the first gene therapy to gain regulatory approval for the treatment of RPE65 -associated Leber congenital amaurosis (LCA) with over 150 patients having received treatment either as part of clinical trials or post-approval globally (Fischer et al. 1 ; Russell et al. 2 ).”
Self-citationUltrasound-Enhanced Retinal Delivery of Engineered Viral Vectors
Link, S. S., Fan, K., Adame, J., Keehn, C. C., Shen, G., Frankfort, B. J., & Szablowski, J. (2026) · Investigative Ophthalmology & Visual Science · doi:10.64898/2026.01.04.697446
Singh, V., Huda, S., Kumar, G. N., & Jayandharan, G. R. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05485-2
Westbay, J. H., Bigley, D. P., Sappa, S., Ayalon, A., Aweidah, H., Dignam, L. D., Martel, J. N., Beltran, W. A., Sahel, J., Byrne, L. C., et al. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb00267f
Karakosta, C., Al‐Khuzaei, S., Clouston, P., Shanks, M. E., & Downes, S. M. (2026) · Vision · doi:10.3390/vision10020021
“Structural imaging using SD-OCT and FAF was used to in the RPE65 -associated retinal dystrophy (Voretigene neparvovec-rzyl—Luxturna ® ) trial as part of the natural history characterization and post-treatment follow-up [15].”
Salameh, M., Schneider, N., Valensi, J., Sarma, A. S., Levanon, E. Y., Ben‐Aroya, S., & Sharon, D. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101475
Testa, F., Iorio, V. D., Melillo, P., Karali, M., Iodice, C. M., Pisani, D., Iovino, C., Banfi, S., Rossi, S., della Corte, M., et al. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.5.9
Self-citationEamegdool, S. S., Loi, T. H., Sabri, A., Karam, F. C., Cheng, A., Lisowski, L., Grigg, J., Alexander, I. E., & Jamieson, R. V. (2026) · Gene Therapy · doi:10.21203/rs.3.rs-9298568/v1
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Self-citationNavigating the spectrum of inherited retinal diseases
YU, M., Vieta-Ferrer, E. R., & DING, X. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00007-0
Texeira, C. H. M., da Palma, M. M., Vasconcelos, H., & Sallum, J. M. F. (2026) · Ophthalmic Genetics · doi:10.1080/13816810.2026.2667307
“Various studies have reported significant improvements in FST after voretigene neparvovec-rzyl therapy, indicating increased light sensitivity (3, 4, 6, 7, 19, 20, 26, 35).”
Khan, Z., Ghazi, N. G., Hay, S., & Khan, A. O. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.06.012
Clinical and genetic characteristics of RPE65-associated inherited retinal degeneration in Koreans
Hwang, S., Jeon, S., Yoon, C. K., Ryu, C. K., Lee, E. K., & Kim, S. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-59093-7
Storage and Stability of AAV-Containing Fibrin Hydrogels for Retinal Gene Therapy
Berger, A., Knudsen, T., Kopp, F., Korda, D., Lang, M. V., Scruggs, B. A., & Marmorstein, A. D. (2026) · Gels · doi:10.3390/gels12070591
“In a systematic review of viral gene therapy clinical trials utilizing subretinal injections, 11.6% (51 of 438) of eyes receiving treatment experienced a severe adverse event [2], the majority of which were retinal degeneration [10,11].”
InfluentialLi, J. X. L., Rowson, A. C., Naji, L., Li, S., & Simunovic, M. P. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.07.001
Amato, A., Iarossi, G., & Stephenson, K. A. J. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.07.039
Perivascular Astrocytic Gliosis Induced by Retinal Gene Therapy
Elsayed, M. E. A. A., Seitz, I. P., Fischer, M. D., & MacLaren, R. E. (2026) · Human Gene Therapy · doi:10.1177/10430342261469741
Self-citationBuin, X., Ghanem, R., Pankonien, I., Becq, F., Amaral, M. D., & Montier, T. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18081040 · Cited by 1
“However, AAV vectors are already used in gene therapy for other diseases such as inherited retinal dystrophy [30].”
Lloyd, A., Király, P., Christou, E. E., Ashworth, J. L., Jalil, A., & Ivanova, T. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-273165
Biomaterials in Retinal Surgery: Engineering the Future
Dindar, I. A., Shoichet, M. S., Labriola, J. M., Forman, A., & Devenyi, R. G. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.08.039
Voretigene Neparvovec (Luxturna) for Biallelic RPE65–Associated Retinal Dystrophy: Systematic Review
Butt, A. B., Zaman, M., Mihalache, A., KamaliZonouzi, S., Zadeh, P. B., Shah, Y. R., Popovic, M. M., Kertes, P. J., Ballios, B. G., Vincent, A., et al. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.08.043
Moraes, T. B. S., Mota, G. R., Jubé, C. P., & MOREIRA, G. S. T. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711175
Câncer de colo uterino avançado: um câncer evitável?
Zunino, A. X., Vasconcellos, B. O., Pinto, A. B. P. S. M. D. F., Leal, G. L. S., & Veloso, P. D. O. M. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711201
CORTISOL, ESTRESSE CRÔNICO E A EXAUSTÃO EMOCIONAL: O EIXO HPA COMO BIOMARCADOR DO BURNOUT
Pereira, I. C., Dias, R. S., de Oliveira, R. G., da Silva, A. L. B., & Toscano, S. S. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711143
IMPACTOS DO USO DE TELAS NA SAÚDE MENTAL DE CRIANÇAS E ADOLESCENTES: RISCOS E OPORTUNIDADES
Serrano, A. R. B., da Silva, R. B., Gonçalves, C. E., Pinto, J. G. C., Soares, J. J. M., Guimarães, T. A. B., Arruda, I. T., Faria, M. E. D. S., y Longo, C. I. D. M., & Rezende, J. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711167
Santos, M. C. D., & Carvalho, R. D. P. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711170 · Cited by 9
TERAPIA GÊRAPIA GÊNICA EM DOENÇAS RETINA: EVIDÊNCIAS RECENTES E IMPLICAÇÕES CLÍNICAS
Mota, G. R., Jubé, C. P., Siqueira, A. C. G., Moraes, T. S. B., & MOREIRA, G. S. T. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711138
ASPECTOS PSIQUIÁTRICOS EM PACIENTES COM LESÕES TRAUMÁTICAS E ATENDIMENTO DE EMERGÊNCIA
da Silva, A. L. B., Pereira, I. C., Dias, R. S., Toscano, S. S., & de Oliveira, R. G. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711142
IMPACTO DA EXPOSIÇÃO À LUZ AZUL DE TECNOLOGIAS DIGITAIS NA SAÚDE OCULAR E NAS PRÁTICAS EDUCATIVAS
Tannus, V. F. S., Barrocas, G., Esposti, R. V. D., & de Souza, C. H. M. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711146
Ciências da saúde: estudos para manutenção e melhoria da vida
(2026) · Editora Conhecimento Livre eBooks · doi:10.37423/2026.edcl1328
Eficácia do belimumab no tratamento da nefrite lúpica: uma revisão sistemática
MACIEL, A. C. D. S., Oliveira, J. V. N., Meira, M. L. X., Guimarães, P. C., & Lopes, A. R. G. (2026) · Editora Conhecimento Livre eBooks · doi:10.37423/260711188
Durable Safety and Efficacy of Voretigene Neparvovec-Rzyl in Postapproval Studies in the USA
Bennett, J. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.08.029
Ducloyer, J., Lemeur, G., Poinas, A., Billaud, F., Vallon, A., Chatry-Konig, R., Giraud, L., Poivet, S., Ivan, C., Saïagh, S., et al. (2026) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2025-002592
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118
Does Route of Administration Affect the Outcome of Retinal Gene Therapy Clinical Trials?
Marmorstein, A. D., Beltran, W. A., & Scruggs, B. A. (2026) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1177/10807683261502683
Metadata
- Authors
- Fischer, M. D., Simonelli, F., Sahni, J., Holz, F. G., Maier, R., Fasser, C., Suhner, A., Stiehl, D. P., Chen, B., Audo, I., & Leroy, B. P.
- Affiliations
- University of Oxford (GB)
- University of Campania "Luigi Vanvitelli" (IT)
- Novartis (Switzerland) (CH)
- University of Bonn (DE)
- Retina International, D02 TW98 Dublin, Ireland; Retina Suisse, 8005 Zürich, Switzerland
- Novartis (United States) (US)
- Centre National de la Recherche Scientifique (FR)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Fischer, M. Dominik
- ORCID
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2024-01-17
- Volume
- 14
- Issue
- 1
- Pages
- 122
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC10813228
- OpenAlex
- W4390944289
- Cited by
- 70
- References
- 18
- Citations by year
- 2026: 31 · 2025: 32 · 2024: 7
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Novartis Pharma AG
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- voretigene neparvovec, gene therapy, real-world safety, long-term effectiveness, chorioretinal atrophy, intraocular inflammation, intraocular infection, visual acuity
- MeSH terms
- Adult, Female, Humans, Male, Prospective Studies, Registries, Retina, Genetic Therapy, Choroid Diseases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.